E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
HER2 negative invasive breast cancer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if patients with HER2 negative early breast cancer receiving a standard regimen of neo-adjuvant chemotherapy with Avastin show better rates of complete pathological response. |
|
E.2.2 | Secondary objectives of the trial |
•Disease-Free Survival
•Overall Survival
•Rate of breast conservation
•pathCR rate in breast alone
•Safety and toxicity
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ARTemis-SCIENCE:
Tumour tissue samples from paraffin-embedded blocks obtained at initial diagnosis and surgery, will be collected from all patients. Analysis of tumour tissue will involve (i) tissue microarrays for immunohistochemistry (IHC) of protein gene products and in situ hybridisation analysis, and (ii) whole-genome profiling using expression and DNA microarrays.
Blood samples will be used to discover single nucleotide polymorphisms (SNPs) as genetic / pharmacogenetic determinants of prognosis, toxicity and treatment outcome.
OPTIONAL Quality of Life sub-study:
All women patients will be invited to take part. Standardised measures of quality of life collected pre-chemotherapy, after 3 cycles, 6 cycles, surgery and radiotherapy, and then annually for 2 years from completion of chemotherapy.
OPTIONAL CTCR-BR05 sub-study:
Fresh tissue samples will also be collected from a sub-set of up to 400 patients before, during, and after neoadjuvant chemotherapy.
Analysis of tumour tissue will involve assessment of prospective predictive high throughput molecular profiling, with candidate gene and mutational analysis.
OPTIONAL Sequential blood samples sub-study:
Blood samples (20mls) will be taken 5 times in a subset of patients and will be collected in order to carry out isolation of specific cells and also measurement of DNA, RNA or proteins. This information will be matched with clinical information to try to identify markers predicting patients response to chemotherapy or bevacizumab.
OPTIONAL Samples Collection At Relapse and Follow-up (SCARF) sub-study:
Blood samples (20mls) will be taken at each follow-up visit (up to and including year 5); and at relapse (if applicable), in order to carry out isolation of specific cells and also measurement of DNA, RNA or proteins. Tissue samples of relapsed / metatstatic site(s) (as is reasonably practical) will also be collected.
This information will be matched with clinical information to try to identify markers predicting patients response / resistance to chemotherapy or bevacizumab.
OPTIONAL MAN-ACT Radiology sub-study (lead site only):
1H MRS, DWI & DCE MRI to assess and predict treatment response. 5 radiography scans at pre-treatment, before cycle 2, after cycle 3 and after cycle 6 in 20 - 30 patients. Also a 30ml blood sample is collected pre-treatment, immediately after cycle 1, before cycle 2, after cycle 3, after cycle 6 and post surgery for research into activity of Circulating Tumour Cells. |
|
E.3 | Principal inclusion criteria |
- Patients with histological diagnosis of HER2 negative invasive breast cancer.
• UNIFOCAL TUMOUR :
- T2 or T3 tumours (radiological size > or = 20 mm).
- T4 tumour of any size with direct extension to (a) chest wall or (b) skin.
OR
Inflammatory carcinoma with tumour of any size.
OR
• OTHER LOCALLY ADVANCED DISEASE:
- Involvement of large or fixed axillary lymph nodes (radiological diameter >20 mm or clinical N2) and primary breast tumour of any diameter.
- Where no primary breast tumour was found, the presence of breast cancer in a lymph node (LN) must be histopathologically confirmed by LN biopsy
(trucut or whole LN).
OR
• MULTIFOCAL TUMOURS:
- The sum of each tumours’ maximum diameter must be > OR = 20mm (total radiological tumour size > 20mm).
- Patients with bilateral disease are eligible to enter the trial.
- Any hormone receptor status.
- Patient fit to receive the trial chemotherapy regimen
- Patient must not have clinically significant cardiac abnormalities and must not have had a previous myocardial infarction during the 6 months prior to recruitment. Cardiac function should be assessed by physical examination and by baseline measurement of LVEF.
- Patient must have adequate bone marrow, hepatic, and renal function.*
- ECOG performance status of 0, 1, or 2
- No previous chemotherapy or endocrine therapy.
- No previous diagnosis of malignancy unless: managed by surgical or radiological treatment only, and disease-free for 10 years, or previous basal cell carcinoma, cervical carcinoma in situ or ductal carcinoma in situ of the breast treated by surgery only.
- Non-pregnant and non-lactating, with no intention of pregnancy during chemotherapy, and prepared to adopt adequate barrier contraceptive measures if there is any possibility of pregnancy (males and females).
- No concomitant medical or psychiatric problems that might prevent completion of treatment or follow-up.
- 18 years or older
- Male or female
- Written informed consent for the study.
- Randomisation is recommended within 4 weeks of biopsy and chemotherapy should start 1 week after randomisation
- Availability of paraffin embedded tumour blocks, from pre-chemotherapy biopsy and from surgical specimen, with corresponding slides, is required.
- Adequate hepatic function defined as
- AST/ALT <1.5xULN
- Alkaline phosphatase ≤2xULN
- Bilirubin within normal range. If AST/ALT and Alkaline phosphatase are within normal limits then isolated elevation of bilirubin to ≤3xULN and a presumptive diagnosis of Gilbert’s syndrome is permitted.
- Adequate renal function with Creatinine ≤1.5xULN
- Adequate bone marrow function defined as
- Hb≥10 g/dL; WBC≥3xunits/L; platelets> 100xunits/L
- Prothrombin time (PT) and Partial thromboplastin time (PTT/ aPTT) ≤1.5xULN. |
|
E.4 | Principal exclusion criteria |
•HER2 positive invasive breast cancer (IHC 3+ or FISH positive)
•T0 and T1 tumours in absence of large (total tumour size >20mm) or fixed axillary nodes
•Evidence of metastatic disease.
•Prior diagnosis of ishaemic heart disease, cerebrovascular disease, peripheral vascular disease, arterial or venous thromboembolic disease, cardiac failure
•Prior diagnosis of gastroduodenal ulcer, symptomatic diverticulitis, inflammatory bowel disease.
•Bleeding diathesis.
•On therapeutic full dose of anti-coagulants, aspirin, clopidogrel or corticosteroids
•Uncontrolled hypertension defined by a systolic pressure >150mmHg and/or
diastolic pressure >90mmHg, with or without anti-hypertensive medication. Patients with initial blood pressure elevations are eligible if initiation or adjustment of antihypertensive medication lowers pressure to meet entry criteria.
•Presence of active uncontrolled infection
•History of nephritic or nephrotic syndrome
•Major surgical procedure or traumatic injury within 28 days prior to randomisation.
•Any evidence of other disease which in the opinion of the investigator places the patient at high risk of treatment related complication.
•Any concomitant medical or psychiatric problems which in the opinion of the investigator would prevent completion of treatment or follow-up.
•Non-healing wound, or peptic ulcer, or bone fracture.
•On LHRH-agonists for ER strongly positive disease
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Complete pathological response (pathCR) rates (tumour and lymph nodes) after neoadjuvant chemotherapy defined as no residual invasive carcinoma within the breast (DCIS permitted) AND no evidence of metastatic disease within the lymph nodes. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
We aim to have completed analysis of the primary endpoint within 3 years of recruitment completion. |
|
E.5.2 | Secondary end point(s) |
• Disease-Free Survival
• Overall Survival
• pathCR rate in breast alone
• Radiological (ultrasound) response after 3 and after 6 cycles of chemotherapy.
• Rate of breast conservation
• Toxicities and safety |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
We aim to have completed analysis of the secondary endpoints within 3 years of recruitment completion. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 67 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the intervention period of the trial will be 1 year after the last patient completes trial treatment (expected to be approximately second quarter 2013). The non-interventional observation period of the trial will continue for at least 10 years following the completion of surgery of the last patient to enter the trial (per the follow-up protocol mentioned above); projected to be 2023. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 14 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |